No Label Ventures

No Label Ventures (NLV) is a London-based European pre-seed and seed-stage venture capital fund founded in 2022 and publicly launched in March 2023. The fund is led by solo General Partner Ramzi Rafih, whose family fled Lebanon during the civil war. Rafih began his career at J.P. Morgan and spent more than a decade as a late-stage investor at KKR and Silver Lake before transitioning to VC; approximately one-third of NLV's fund is anchored by his former KKR colleagues. NLV focuses exclusively on Europe and is positioned as the first institutional backer specifically for immigrant entrepreneurs, providing first cheques from day one before a lead VC commits. The fund writes tickets of $150,000 to $250,000, with the ability to upscale via LP co-investment. It is sector agnostic across SaaS, developer tools, SMB software, AI, biotech, agtech, climate tech, marketplaces, fintech, and therapeutics. Across nine disclosed investments, portfolio companies include Spore.Bio, which produces FMCG quality-control devices; Callyope, a speech-based remote patient monitoring company that raised a EUR 2.2 million round; Pangea Bio; Zango; Nozomio Labs; and POSTX. Several NLV-backed companies have gone on to raise from Sequoia Capital and other leading European and US firms. NLV's thesis rests on a documented investment inefficiency: immigrant founders in Europe typically raise at 14 percent lower valuations with 24 percent less funding, yet outperform better-capitalised peers by up to 70 percent. By providing unconditional first capital, visa and immigration workflow support, customer introductions, and downstream fundraising guidance, NLV offers a package of support that extends well beyond the cheque itself.